Imac Holdings, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
OTC.Pink
10-K/A: IMAC Holdings Pivots to Oncology Proteomics Amidst Financial Restatement and Nasdaq Delisting
IMAC Holdings, Inc. has undergone a significant strategic shift, divesting its previous patient care operations to focus entirely on oncology proteomics, while simultaneously addressing a financial restatement and navigating a delisting from Nasdaq.
OTC.Pink
10-K: IMAC Holdings Shifts Focus to Proteomics After Selling Patient Care Assets; Faces Nasdaq Delisting
IMAC Holdings transitions to proteomic services, acquiring Theralink assets, while grappling with Nasdaq delisting due to Minimum Equity Rule non-compliance.
OTC.Pink
IMAC Holdings files an amended 10-K, restating its financials and detailing its strategic shift away from clinic operations towards a merger with Theralink Technologies.
OTC.Pink
IMAC Holdings, Inc. ceased operations at all outpatient medical clinics and BackSpace locations by the end of 2023, shifting focus to strategic alternatives.